There’s something compelling about a biotech grounded in precision. Arthrosi Therapeutics isn’t out here swinging for buzzwords, they’re engineering clarity in a field where pain literally calcifies. The San Diego-based company just closed a $153 M Series E, led by Prime Eight Capital Limited with backing from CR Biotech, HighLight Capital, HM Venture Partners, ReliantTech Limited, and returning believers. That brings total funding to roughly $228M, a number that doesn’t just measure capital, it measures conviction in what’s coming next.
Founded in 2018 by Litain Yeh, Ph.D., Arthrosi has been quietly rewriting the physiology of gout while others were still rewriting pitch decks. Dr. Yeh isn’t just a founder; he’s a small-molecule tactician who knows inflammation on a molecular level. Alongside Shunqi Yan, Ph.D., the company’s COO and fellow founder, the duo has pushed Arthrosi from concept to late-stage biotech contender with a pipeline laser-focused on one mission, ending gout’s long, ugly reign of flare-ups and pain.
Their lead act? Pozdeutinurad (AR882). A next-gen URAT1 inhibitor that actually walks the talk, lowering serum urate (sUA) levels, reducing flares, and dissolving tophi that once marked lifelong suffering. AR882 isn’t another “me too” molecule; it’s the precision-engineered evolution of how hyperuricemia is treated. Phase 2 data already showed rapid, clinically meaningful sUA reduction and visible tophi resolution verified by DECT imaging. No wild drug-drug interactions, no messy pharmacokinetics, just smart chemistry doing its job.
Now, with both pivotal Phase 3 REDUCE 1 and REDUCE 2 trials fully enrolled, Arthrosi is stepping into the money round. 750 patients across the REDUCE 2 study locked in by Mar 2025, and REDUCE 1 crossed the line this fall. Top-line data are on deck for Q2 and Q4 2026, with NDA submission already in motion. For a disease affecting 13M people in the U.S. (~2 M with tophaceous gout), the stakes aren’t academic, they’re human.
Here’s the quiet brilliance: while others chase novelty for the sake of headlines, Arthrosi chased pharmacologic perfection. 14 patents deep, no shortcuts, no gimmicks. That’s how you build trust in an industry where results are the only currency that matters.
This Series E isn’t just fuel, it’s validation that disciplined science still wins. Prime Eight Capital and its syndicate didn’t buy a headline; they bought into a future where gout becomes a treatable chapter, not a lifelong sentence.
